We also lack the comprehensive consideration of clinical characteristics including age, response to different treatments, and recurrence rate in patients with different molecular subtypes, especially the hormone receptor-positive luminal vs. basal/triple-negative breast cancer (49–51). Here, NR4A1 is linked to triple-negative breast carcinoma.